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Background: Chronic renal insufficiency (CRI) is an established risk factor for coronary disease, but its effect upon high on-treatment platelet 
reactivity in patients following percutaneous coronary intervention is not well understood.
Methods: 200 patients received 600 mg of clopidogrel and underwent platelet reactivity testing with VerifyNow P2Y12 (VN) at 6 to 24 hours after 
PCI. High on-treatment platelet reactivity (HOPR) was defined as maximum platelet reactivity units ≥235 for VN. CRI was defined as serum creatinine 
≥2.0 mg/dL with previously diagnosed renal insufficiency treated by a physician. Univariable association between CRI and HOPR was evaluated with 
the chi-square test, and multivariable association was evaluated with logistic regression.
Results: 14% of patients had a history of CRI. 45% of patients with CRI had HOPR, compared to 24% of patients without HOPR (p=0.02). Patients 
with CRI were also older (69 vs. 62 years, p=0.006), and more likely to be diabetic (55% vs. 31%, p=0.01) or have a history of congestive heart 
failure (45% vs. 13%, p<0.001). Following multivariable adjustment for diabetes, congestive heart failure, presentation with acute myocardial 
infarction, and body mass index, CRI remained significantly associated with HOPR.
Conclusions: Poor outcomes in patients with CRI undergoing PCI may be in part due to increased levels of platelet reactivity. such patients may 
benefit from more aggressive platelet inhibition. 
Odds Ratio 95% Confidence Interval p value
Chronic renal insufficiency 2.58 1.05-6.36 0.04
Diabetes mellitus 1.44 0.70-2.99 0.33
Congestive heart failure 1.30 0.55-3.08 0.55
Acute myocardial infarction 2.17 0.86-5.44 0.10
Body mass index 1.05 0.99-1.11 0.10
